{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T22:37:56Z","timestamp":1782254276612,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,7,29]],"date-time":"2017-07-29T00:00:00Z","timestamp":1501286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,7,29]],"date-time":"2017-07-29T00:00:00Z","timestamp":1501286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["GM109645"],"award-info":[{"award-number":["GM109645"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["CA205224"],"award-info":[{"award-number":["CA205224"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s00280-017-3401-y","type":"journal-article","created":{"date-parts":[[2017,7,29]],"date-time":"2017-07-29T16:03:05Z","timestamp":1501344185000},"page":"861-867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition"],"prefix":"10.1007","volume":"80","author":[{"given":"Gayathri","family":"Srinivasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurjit Singh","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruna S.","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasreen","family":"Najmunnisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Wilcoxen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennie","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Thomas J.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1916-6276","authenticated-orcid":false,"given":"Robert","family":"Hromas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,29]]},"reference":[{"key":"3401_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1177\/1753465816628800","volume":"10","author":"S Kondola","year":"2016","unstructured":"Kondola S, Manners D, Nowak AK (2016) Malignant pleural mesothelioma: an update on diagnosis and treatment options. Ther Adv Respir Dis 10:275\u2013288. doi:\n                    10.1177\/1753465816628800","journal-title":"Ther Adv Respir Dis"},{"key":"3401_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s11864-014-0314-4","volume":"15","author":"D Gomez","year":"2014","unstructured":"Gomez D, Tsao AS (2014) Local and systemic therapies for malignant pleural mesothelioma. Curr Treat Options Oncol 15:683\u2013699. doi:\n                    10.1007\/s11864-014-0314-4","journal-title":"Curr Treat Options Oncol"},{"key":"3401_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145039","author":"E Taioli","year":"2015","unstructured":"Taioli E, Wolf AS, Camacho-Rivera M et al (2015) Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) Study of 14,228 Patients. PLoS One. doi:\n                    10.1371\/journal.pone.0145039","journal-title":"PLoS One"},{"key":"3401_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD et al (2016) Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 48:407\u2013416. doi:\n                    10.1038\/ng.3520","journal-title":"Nat Genet"},{"key":"3401_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","volume":"10","author":"M Nasu","year":"2015","unstructured":"Nasu M, Emi M, Pastorino S et al (2015) High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol 10:565\u2013576. doi:\n                    10.1097\/JTO.0000000000000471","journal-title":"J Thorac Oncol"},{"key":"3401_CR6","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa JR, Cheung M, Pei J et al (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43:1022\u20131025. doi:\n                    10.1038\/ng.912","journal-title":"Nat Genet"},{"key":"3401_CR7","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott M, Brevet M, Taylor BS et al (2011) The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43:668\u2013672. doi:\n                    10.1038\/ng.855","journal-title":"Nat Genet"},{"key":"3401_CR8","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1158\/0008-5472.CAN-15-3371","volume":"76","author":"Y Kadariya","year":"2016","unstructured":"Kadariya Y, Cheung M, Xu J et al (2016) Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations. Cancer Res 76:2836\u20132844. doi:\n                    10.1158\/0008-5472.CAN-15-3371","journal-title":"Cancer Res"},{"key":"3401_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1073\/pnas.1309085110","volume":"111","author":"H Yu","year":"2014","unstructured":"Yu H, Pak H, Hammond-Martel I et al (2014) Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci USA 111:285\u2013290. doi:\n                    10.1073\/pnas.1309085110","journal-title":"Proc Natl Acad Sci USA"},{"key":"3401_CR10","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-13-3109","volume":"74","author":"IH Ismail","year":"2014","unstructured":"Ismail IH, Davidson R, Gagn\u00e9 JP et al (2014) Germline mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Res 74:4282\u20134294. doi:\n                    10.1158\/0008-5472.CAN-13-3109","journal-title":"Cancer Res"},{"key":"3401_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/1568009615666151030102427","volume":"16","author":"T Fukuda","year":"2016","unstructured":"Fukuda T, Tsuruga T, Kuroda T et al (2016) Functional link between BRCA1 and BAP1 through histone H2A, heterochromatin and DNA damage response. Curr Cancer Drug Targets 16:101\u2013109. doi:\n                    10.2174\/1568009615666151030102427","journal-title":"Curr Cancer Drug Targets"},{"key":"3401_CR12","doi-asserted-by":"publisher","first-page":"6074","DOI":"10.1182\/blood-2011-01-313734","volume":"117","author":"M Shaheen","year":"2014","unstructured":"Shaheen M, Allen C, Nickoloff JA, Hromas R (2014) Synthetic lethality: exploiting the addiction of cancer to DNA repair. Review article. Blood 117:6074\u20136082. doi:\n                    10.1182\/blood-2011-01-313734","journal-title":"Blood"},{"key":"3401_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s11684-012-0197-3","volume":"6","author":"Z Wang","year":"2012","unstructured":"Wang Z, Wang F, Tang T, Guo C (2012) The role of PARP1 in the DNA damage response and its application in tumor therapy. Front Med China 6:156\u2013164. doi:\n                    10.1007\/s11684-012-0197-3","journal-title":"Front Med China"},{"key":"3401_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pgen.1005675","volume":"11","author":"Y Wu","year":"2015","unstructured":"Wu Y, Lee SH, Williamson EA et al (2015) EEPD1 rescues stressed replication forks and maintains genome stability by promoting end resection and homologous recombination repair. PLoS Genet 11:1\u201329. doi:\n                    10.1371\/journal.pgen.1005675","journal-title":"PLoS Genet"},{"key":"3401_CR15","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1182\/blood-2012-10-460527","volume":"121","author":"J Wray","year":"2013","unstructured":"Wray J, Williamson EA, Singh SB et al (2013) PARP1 is required for chromosomal translocations. Blood 121:4359\u20134365. doi:\n                    10.1182\/blood-2012-10-460527","journal-title":"Blood"},{"key":"3401_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/BF00294917","volume":"58","author":"E Gebhart","year":"1981","unstructured":"Gebhart E (1981) Sister chromatid exchange (SCE) and structural chromosome aberration in mutagenicity testing. Hum Genet 58:235\u2013254. doi:\n                    10.1007\/bf00294917","journal-title":"Hum Genet"},{"key":"3401_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mrgentox.2016.03.011","volume":"803\u2013804","author":"D Mourelatos","year":"2016","unstructured":"Mourelatos D (2016) Sister chromatid exchange assay as a predictor of tumor chemoresponse. Mutat Res Genet Toxicol Environ Mutagen 803\u2013804:1\u201312. doi:\n                    10.1016\/j.mrgentox.2016.03.011","journal-title":"Mutat Res Genet Toxicol Environ Mutagen"},{"key":"3401_CR18","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1021\/jm5018237","volume":"58","author":"P Jones","year":"2015","unstructured":"Jones P, Wilcoxen K, Rowley M, Toniatti C (2015) Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination. J Med Chem 58:3302\u20133314. doi:\n                    10.1021\/jm5018237","journal-title":"J Med Chem"},{"key":"3401_CR19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J et al (2016) Niraparib maintenance therapy in platinum-sensitive recurrent ovarian cancer. N Engl J Med. doi:\n                    10.1056\/NEJMoa1611310\n                    \n                   \n                           (NEJMoa1611310)","journal-title":"N Engl J Med"},{"key":"3401_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/mutage\/geq052","volume":"26","author":"M Fenech","year":"2011","unstructured":"Fenech M, Kirsch-Volders M, Natarajan AT et al (2011) Molecular mechanisms of micronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and human cells. Mutagenesis 26:125\u2013132. doi:\n                    10.1093\/mutage\/geq052","journal-title":"Mutagenesis"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3401-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3401-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3401-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T11:30:53Z","timestamp":1589628653000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3401-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,29]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["3401"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3401-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,29]]},"assertion":[{"value":"13 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This work was supported by NIH GM084020, GM109645, and CA205224 to RH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"KW is employed by and holds equity in Tesaro, which owns the rights to niraparib. Tesaro did not provide any funding for this work. Every other author declares that they do not have any conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human subjects"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal care"}}]}}